New dengue vaccine shows promise in japan trial

NCT ID NCT06741683

Completed ⭐️ VACCINE ⭐️ Sponsor: Takeda Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a dengue vaccine (TDV) in 187 healthy Japanese volunteers aged 4 to 60. Participants received two shots three months apart. The main goal was to see if the vaccine triggers an immune response against all four types of dengue virus. The trial is now complete.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dengue tetravalent vaccine (live, attenuated) also known as TAK-003
What this could lead to: If successful, this vaccine could help prevent dengue fever in people living in or traveling to Japan.
What could go wrong: This is a relatively small, completed trial focused on immune response, not actual disease prevention. Results may not guarantee protection in real-world outbreaks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DENGUE FEVER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dengue disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DENGUE FEVER

Contacts and locations

Locations

OKURA Otolaryngology Clinic

Toshima-ku, Tokyo, Japan
PS Clinic

Fukuoka, Fukuoka, Japan
Saitama City Hospital

Saitama-shi, Saitama, Japan
Sumida Hospital

Sumida-ku, Tokyo, Japan
Tamura Clinic

Tokyo, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.